Vortioxetine: Clinical Trials

19 trials of Vortioxetine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 3 recruiting, 3 unknown. 19 Phase 2, 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 219Completed 13, Recruiting 3, Unknown 3
Phase 34Completed 3, Unknown 1
Phase 11Recruiting 1

Follow Vortioxetine: new trials by email Literature Review of Vortioxetine trials Research Report on Vortioxetine

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vortioxetine for Newly Diagnosed Glioblastoma
Vortioxetine - Glioblastoma
Phase 2RecruitingUniversity of Zurich782026-06-242026-06-29
Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study
Risk managment, Dasatinib, Quercetin (dietary supplement) - Aging, Cognitive Decline
Phase 2CompletedWashington University School of Medicine232025-07-282026-08-19
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
Vortioxetine - Fronto-temporal Dementia, Fronto-temporal Lobar Dementia
Phase 2RecruitingJohns Hopkins University502025-03-202026-03-09
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
Fluoxetine, Sertraline, Vortioxetine - Depression, Sequestra
Phase 1 / Phase 2RecruitingFirst Affiliated Hospital of Chongqing Medical University5202023-02-202026-01-27
Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia
Vortioxetine, Usual Antipsychotic Treatment - Cognitive Impairment With Primary Psychotic Disorder, Negative Symptoms With Primary Psychotic Disorder
Phase 2 / Phase 3UnknownFundación Pública Andaluza para la gestión de la Investigación en Sevilla372022-01-202024-02-26
Vortioxetine for Post-COVID-19 Condition
Vortioxetine, Placebo - Post-COVID-19 Condition, Post-COVID-19 Syndrome
Phase 2CompletedBrain and Cognition Discovery Foundation1492021-09-162025-01-16
Vortioxetine for Treatment of Depressive Mood and Alcohol Use
Vortioxetine, Acamprosate - Depressive Disorder, Major, Alcoholism
Phase 2UnknownHanyang University Seoul Hospital1282019-01-252020-08-05
Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression
Vortioxetine infusion 25 mg, Vortioxetine tablets 10 mg/day, Placebo infusion - Major Depressive Disorder
Phase 2CompletedH. Lundbeck A/S802018-12-032019-08-29
Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression
Vortioxetine, Placebo - Bipolar Disorder Depression
Phase 2UnknownSeoul National University Hospital1002018-08-082018-08-10
Substance Misuse To Psychiatric Disorders for Cannabis
Vortioxetine, Treatment as Usual - Cannabis Use Disorder, Depressive State
Phase 2 / Phase 3CompletedThe University of Hong Kong372018-07-252023-07-05
THINC-it Vortioxetine - Sensitivity to Change
Vortioxetine, THINC-it Tool - Major Depressive Disorder, Cognitive Change
Phase 2 / Phase 3CompletedBrain and Cognition Discovery Foundation1582017-05-242025-06-08
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
Vortioxetine (IV), Placebo (IV), Vortioxetine (tablet) - Depressive Disorder, Major
Phase 2CompletedH. Lundbeck A/S552016-09-272018-06-20
Vortioxetine for Binge Eating Disorder
Vortioxetine, Placebo - Binge Eating Disorder
Phase 2CompletedUniversity of Chicago802016-06-012020-11-23
Investigating the Effect of Vortioxetine in Adult ADHD Patients
vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet - Attention Deficit Hyperactivity Disorder
Phase 2CompletedH. Lundbeck A/S2272014-12-012018-03-07
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
vortioxetine (Lu AA21004), Duloxetine, Placebo - Depressive Disorder, Major
Phase 2CompletedTakeda6022012-04-012015-02-05
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
Vortioxetine - Depressive Disorder, Anxiety Disorder
Phase 2CompletedH. Lundbeck A/S482012-04-012017-03-16
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
Vortioxetine, Placebo - Depressive Disorder, Major
Phase 2 / Phase 3CompletedTakeda6002010-11-012013-12-18
Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
Vortioxetine (Lu AA21004) - Major Depressive Disorder
Phase 2CompletedH. Lundbeck A/S742007-06-012014-01-29
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
Placebo, Vortioxetine (Lu AA21004), Venlafaxine XL - Major Depressive Disorder
Phase 2CompletedH. Lundbeck A/S4262006-08-012014-05-13

Conditions studied

Depressive Disorder, Major (8)  ·  Depression (3)  ·  Anxiety Disorders (2)  ·  Cognitive Dysfunction (2)  ·  Depressive Disorder (2)  ·  Alcoholism (1)  ·  Attention Deficit Disorder with Hyperactivity (1)  ·  Binge-Eating Disorder (1)  ·  Bipolar Disorder (1)  ·  Cognition Disorders (1)  ·  Fatigue (1)  ·  Frontotemporal Dementia (1)  ·  Glioblastoma (1)  ·  Marijuana Abuse (1)  ·  Mental Fatigue (1)

Sponsors

H. Lundbeck A/S (6)  ·  Brain and Cognition Discovery Foundation (2)  ·  Takeda (2)  ·  First Affiliated Hospital of Chongqing Medical University (1)  ·  Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1)  ·  Hanyang University Seoul Hospital (1)  ·  Johns Hopkins University (1)  ·  Seoul National University Hospital (1)  ·  The University of Hong Kong (1)  ·  University of Chicago (1)  ·  University of Zurich (1)  ·  Washington University School of Medicine (1)

Countries

United States (6)  ·  Finland (3)  ·  Germany (3)  ·  South Korea (3)  ·  Bulgaria (2)  ·  Canada (2)  ·  Estonia (2)  ·  Hong Kong (2)  ·  Latvia (2)  ·  Poland (2)  ·  Russia (2)  ·  Ukraine (2)  ·  China (1)  ·  Croatia (1)  ·  India (1)

Top investigators

Albert KK Chung, MBBS(HK) (1)  ·  Benedicto Crespo Facorro, Professor (1)  ·  Christopher Morrow, MD (1)  ·  Eric Lenze, MD (1)  ·  Jon E Grant, JD, MD, MPH (1)  ·  Roger McIntyre (1)  ·  Roger S. McIntyre, MD, FRCPC (1)  ·  Sungwon Roh (1)  ·  Yong Min Ahn, MD, PHD (1)

Results publications

PMID 21767441, PMID 28213121, PMID 28858412, PMID 29035574, PMID 29235884, PMID 29546401, PMID 29689693, PMID 30439678, PMID 30766492, PMID 31094901, PMID 31404802, PMID 31422713, PMID 32670103, PMID 32784346, PMID 36708956, PMID 37891522, PMID 38114867, PMID 38424537, PMID 38520501, PMID 38860901, PMID 38954402

NIH funding

2015 (1), K23AG088248 (1)